Formoterol: all 179 studies that test it
Page 2 of 2. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.
- Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/SalmeterolTerminatedNCT02491970Phase 4
- Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol in Asthma PatientsCompletedNCT02415179Not applicable
- Pharmacokinetics and Safety Study of PT010 in Healthy SubjectsCompletedNCT02189304Phase 1
- Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD PatientsCompletedNCT02119234Phase 1
- A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment.CompletedNCT02040597Phase 1
- Effects of Particle Size in Small Airways DysfunctionCompletedNCT01892787Phase 4
- Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients - SANOB StudyCompletedNCT01853787Phase 4
- A Randomized Comparative Effectiveness Research Trial of Three Treatments for COPD PatientsStatus unknownNCT01836016Phase 3
- Effect of Symbicort on Sleep Quality in Patients With EmphysemaStatus unknownNCT01602523Phase 3
- Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell TransplantationCompletedNCT01560689Phase 2
- Efficacy Study of the Product "CHF 1535" Versus Beclomethasone (BDP) and Free Combo in Asthmatic ChildrenCompletedNCT01475032Phase 3
- Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways FunctionStatus unknownNCT01466712Phase 4
- Pharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy VolunteersCompletedNCT01398111Phase 1
- Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed TomographyStatus unknownNCT01361984Phase 4
- PT005 MDI Dose Ranging Versus Foradil Aerolizer StudyCompletedNCT01349868Phase 2
- Study to Investigate the Effect of Formoterol vs Salmeterol on Small Airways Physiological Parameters in COPD PatientsCompletedNCT01344655Phase 4
- Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis TurbuhalerCompletedNCT01257048Early Phase 1
- Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01253473Phase 4
- A Study Comparative of Formoterol/Fluticasone Foraseq® and Fluticasone in Asthma PatientsCompletedNCT01202084Phase 3
- Effect on Adrenal Function of Budesonide Versus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01186653Phase 4
- A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01168310Phase 2
- A Study Characterizing Pharmacodynamic Profiles in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT01113593Phase 2
- Effect of Gly16Arg Polymorphism in ADRB2 Gene on Asthma Control in Children Receiving Long Acting Beta AgonistsWithdrawnNCT01108627Phase 4
- A Comparative Study Between Foraseq and Formoterol/Budesonide Inhalation Capsules in Patients with AsthmaCompletedNCT01001364Phase 3
- Differential Trough Effects of 'Triple Therapy' on Pulmonary Function in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00996697Phase 4
- Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate AsthmaCompletedNCT00995800Phase 2
- Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT00972140Phase 3
- Usefulness of Exhaled Breath Condensate for Evaluation of Markers of Airway Inflammation in Children With AsthmaStatus unknownNCT00961155Phase 2
- Concentrations of Formoterol in Blood and UrineStatus unknownNCT00914654Phase 4
- Rapid Onset Action of Salbutamol Versus FormoterolStatus unknownNCT00900874Phase 4
- Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma PatientsCompletedNCT00830102Phase 2
- A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT00774761Phase 2
- Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00742248Phase 2
- Effects of Budesonide & Budesonide/Formoterol on Smoking Asthmatic SubjectsCompletedNCT00691951Phase 3
- Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB)WithdrawnNCT00662779Phase 3
- Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis TurbuhalerCompletedNCT00658255Phase 2
- Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEMCompletedNCT00652392Phase 3
- Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5CompletedNCT00652002Phase 3
- Titratable Dosing in Moderate to Severe AsthmaticsCompletedNCT00651768Phase 3
- Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5CompletedNCT00651651Phase 3
- Symbicort in Asthmatic Children - SEEDLINGCompletedNCT00651547Phase 3
- Symbicort Onset of Action 2CompletedNCT00646009Phase 3
- Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT)WithdrawnNCT00633776Phase 4
- Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCTCompletedNCT00624754Phase 2
- Change of Inspiratory Peak Flow in COPDCompletedNCT00561886Phase 4
- Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPDCompletedNCT00476099Phase 3
- Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)CompletedNCT00443482Phase 2
- Study of Mometasone Furoate/Formoterol Fumarate Inhalation Combination in Healthy VolunteersCompletedNCT00418509Phase 1
- A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT00403286Phase 2
- New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With AsthmaCompletedNCT00394121Phase 3
- Influence Of Different Airflow Resistances On Drug Effect Of 50μg Salmeterol And 6 μg FormoterolCompletedNCT00327353Phase 4
- Prevention of Asthma Relapse After Discharge From EmergencyCompletedNCT00326053Phase 3
- Real Life Effectiveness in Asthma of Symbicort Single Inhaler TherapyCompletedNCT00319306Phase 3
- A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPDCompletedNCT00308191Phase 3
- SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent AsthmaCompletedNCT00290264Phase 3
- SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild AsthmaCompletedNCT00288379Phase 3
- A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate 20 Mcg/0.5 mL in the Treatment of Patients With COPDCompletedNCT00280371Phase 3
- Effect of Budesonide / Formoterol Combination in Repeated AMP ProvocationsCompletedNCT00272753Phase 4
- SYMPHONIE - A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and AdultsCompletedNCT00259792Phase 3
- Comparison Between Symbicort® and Prednisolone in COPDCompletedNCT00259779Phase 3
- Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With AsthmaCompletedNCT00255255Phase 3
- Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic PatientsCompletedNCT00252785Phase 3
- A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®CompletedNCT00244608Phase 3
- Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mgCompletedNCT00242775Phase 3
- SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & AdultsCompletedNCT00238784Phase 3
- Symbicort Single Inhaler Therapy for Asthma in a General Practice SettingCompletedNCT00235911Phase 3
- Study in Patients With COPDCompletedNCT00215449Phase 3
- A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPDCompletedNCT00215436Phase 3
- Study in Patients With COPDCompletedNCT00215423Phase 2
- Study in Patients With AsthmaCompletedNCT00215410Phase 2
- Study in Patients With AsthmaCompletedNCT00215397Phase 2
- Study in Patients With COPDCompletedNCT00215384Phase 2
- Study in Patients With AsthmaCompletedNCT00215371Phase 2
- Study in Patients With AsthmaCompletedNCT00215358Phase 2
- A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPDCompletedNCT00206167Phase 3
- A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD PatientsCompletedNCT00206154Phase 3
- Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)CompletedNCT00139932Phase 4
- Formoterol Certihaler, Tiotropium HandiHaler and Tiotropium HandiHaler in Combination With Formoterol Certihaler in Patients With Stable Chronic Obstructive Pulmonary DiseaseCompletedNCT00134979Phase 4
- To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPDCompletedNCT00064415Phase 3